Back to Newsroom

Cyclacel’s Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and Synergy With Other Anti-Cancer Compounds

BERKELEY HEIGHTS, N.J., April 20, 2015 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced the presentation of preclinical data demonstrating therapeutic potential of CYC065, the Company’s second-generation, cyclin-dependent kinase (CDK) 2/9 inhibitor as a targeted anti-cancer agent. The data showed that CYC065 inhibits key cancer and leukemia survival mechanisms and causes death by apoptosis in cancer cells. CYC065 is effective against acute myeloid leukemia (AML), and in particular, AML with genetic abnormalities such as MLL rearrangements (MLL-r), which confer a poor prognosis. CYC065 was also effective against uterine cancer cells including those resistant to chemotherapy and was especially potent in uterine cancer cells in which cyclin E, the partner protein of CDK2, was amplified or overexpressed. In each case CYC065 showed synergy with available anti-cancer agents. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2015, April 18 – 22, 2015, in Philadelphia. Results from preclinical studies by independent investigators on the Company’s drug candidates sapacitabine and seliciclib, as well as CYC065, are also being presented.

Click here to read more